UTHRNASDAQHealthcare

UNITED THERAPEUTICS CORP

Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.

Latest price

$562.02

-0.65%

Alpha Vantage · 11/6/2026

Industry: BiotechnologyCategory: Domestic Common StockCurrency: USDNews: 1 recent

Analyze UTHR free

One-year price history

Adjusted daily closes · 252 observations · as of Nov 6, 2026

Historical data, not a forecast

1 month

+5.5%

3 months

+6.1%

6 months

-0.5%

1 year

+23.8%

Year to date

+15.3%

52-week range

$448.91 – $608.49

Fundamental snapshot

Latest reported period: Sep 30, 2026

Sharadar reported data

Market cap

$23.94B

P/E

19.4

P/B

3.8

P/S

7.5

Revenue

$3.19B

Net income

$1.23B

Diluted EPS

26.49

Gross margin

86.30%

Net margin

38.60%

Return on equity

19.20%

Total debt

Cash

$1.19B

Free cash flow

$867.2M

Latest eight reported quarters

Reported quarterly values, newest first

Period	Revenue	Net income	Gross margin	Net margin	Free cash flow
Sep 30, 2026	$832.5M	$258.6M	88.10%	31.10%	$125.8M
Jun 30, 2026	$783.3M	$333M	87.30%	42.50%	$205.6M
Mar 31, 2026	$781.5M	$274.9M	82.90%	35.20%	$362.5M
Dec 31, 2025	$790.2M	$364.3M	86.90%	46.10%	$173.3M
Sep 30, 2025	$799.5M	$338.7M	87.40%	42.40%	$351.6M
Jun 30, 2025	$798.6M	$309.5M	89.00%	38.80%	$129.5M
Mar 31, 2025	$794.4M	$322.2M	88.40%	40.60%	$386.3M
Dec 31, 2024	$735.9M	$301.3M	89.70%	40.90%	$254.5M

Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.

Recent UTHR news

All market news

Stock Titan·Nov 6, 202654 signal

Family trusts sell 1,723 United Therapeutics (UTHR) shares under a pre-arranged plan.

Family trusts linked to Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), sold 1,723 common shares on November 4, 2026, under a pre-arranged Rule 10b5-1 trading plan. The sales occurred at weighted-average prices ranging from $610.2928 to $613.1350 per share. This trading plan is scheduled to continue until the earlier of exercising 1,734,410 stock options or December 31, 2026.

Original source